AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:17 11/06/2026 BST			5-day change	1st Jan Change
13,578.00 ^GBX	+0.85%		+0.18%	-1.54%

04:03pm	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
04:03pm	Race to launch weight-loss pill heats up as Novo wins UK approval	RE

ASTRAZENECA : Bernstein reaffirms its Buy rating

Published on 05/04/2026 at 07:11 am BST

MarketScreener with dpa-AFX Analyser

ASTRAZENECA PLC

+0.85%

In a research note published by Justin Smith, Bernstein advises its customers to buy the stock. The target price is decreased from GBX 20500 to GBX 18600.

Latest news about AstraZeneca PLC

04:03pm	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
04:03pm	Race to launch weight-loss pill heats up as Novo wins UK approval	RE
09:51am	ASTRAZENECA : Deutsche Bank maintains a Sell rating	ZD
07:02am	Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal	RE
05:54am	Nordic Stocks in North America - Ericsson slides 1.3 percent	FW
06-10	European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	MT
06-10	Kyntra Bio Receives Final $4 Million Payment Under 2025 Share Purchase Deal With AstraZeneca	MT
06-10	Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon	RE
06-10	Hansa Biopharma appoints Head of Business Development from AstraZeneca	FW
06-10	Nordic stocks in North America - Autoliv rose 1.6 percent	FW
06-09	Stockholm stocks retreat on Tuesday, OMXS30 index sheds 1.2 percent	FW
06-09	What Bundibugyo Ebola vaccines and treatments are under development	RE
06-09	ASTRAZENECA : JP Morgan remains its Buy rating	ZD
06-09	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
06-09	Fragile truce, solid recovery in Europe

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).

Employees

96,100

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company